AURA
Aura Biosciences, Inc. · Healthcare · Market cap $683.4M
Insiders sold $82K net in the last 90 days ·1 seller, 0 buyers· latest Form 4 filed Jun 16, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$40.1M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Sep 1, 2026
Gibney Anthony S
Aura Biosciences, Inc. (AURA) has 32 SEC Form 4 filings (33 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Sep 1, 2026.
Inside the rolling window, 7 insiders at Aura Biosciences, Inc. reported no open-market purchases and 14 open-market sales totaling $40.1M. The most active filer is Senior Vice President, Finance Elazzouzi Amy with 3 filings. Insiders have net sold $39.2M over the trailing 6 months. The most recent open-market filing is a sale of 12,824 shares by See Remarks Gibney Anthony S, dated Jun 16, 2026, worth $82K.
- Industry:Biotechnology
- CEO:Elisabet de los Pinos
- Employees:113
- HQ:Boston, MA, US
- IPO:2021-10-29
| Source | |||||||
|---|---|---|---|---|---|---|---|
Gibney Anthony SFirst filing | See Remarks | Sale | 12,824 | $82K | Jun 16 | +4.9% | SEC ↗ |
Matrix Capital Management Company, LPFirst in 5 months | 10% Owner | Sale | 6,922,870 | $39.0M | May 11 | -19.5% | SEC ↗ |
| See Remarks | Sale | 11,738 | $82K | Apr 16 | -6.7% | SEC ↗ | |
Hopkins Janet JillFirst in 3 months | Chief Medical Officer | Sale | 20,401 | $103K | Feb 17 | +25.5% | SEC ↗ |
Plavsic MarkFirst in 4 months | Chief Technology Officer | Sale | 15,890 | $80K | Feb 17 | +25.5% | SEC ↗ |
| Senior Vice President, Finance | Sale | 8,549 | $43K | Feb 17 | +25.5% | SEC ↗ | |
| See Remarks | Sale | 47,648 | $241K | Feb 17 | +25.5% | SEC ↗ | |
Kilroy ConorFirst filing | See Remarks | Sale | 12,079 | $61K | Feb 17 | +25.5% | SEC ↗ |
| See Remarks | Sale | 16,928 | $82K | Jan 20 | +32.6% | SEC ↗ | |
| Senior Vice President, Finance | Sale | 1,581 | $8K | Jan 20 | +32.6% | SEC ↗ | |
Hopkins Janet JillFirst filing | Chief Medical Officer | Sale | 17,109 | $93K | Nov 17 | — | SEC ↗ |
Elazzouzi AmyFirst filing | Senior Vice President, Finance | Sale | 896 | $6K | Oct 29 | — | SEC ↗ |
de los Pinos ElisabetFirst filing | See Remarks | Sale | 9,049 | $57K | Oct 29 | — | SEC ↗ |
Plavsic MarkFirst filing | Chief Technology Officer | Sale | 12,169 | $77K | Oct 16 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does AURA have?
Aura Biosciences, Inc. (AURA) has 32 SEC Form 4 filings (33 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Sep 1, 2026.
When was the most recent SEC Form 4 filing for AURA?
The most recent Form 4 filing for AURA on Tracefour is dated Sep 1, 2026.
Who is the most active insider at AURA?
The most active SEC Form 4 filer at AURA in the rolling window is Senior Vice President, Finance Elazzouzi Amy, with 3 filings.
What is the net insider flow at AURA over the last 6 months?
Over the trailing 180 days, insiders at AURA have net sold $39.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at AURA in the current window?
Inside the rolling window, insiders at AURA bought $0 and sold $40.1M based on SEC Form 4 filings.
Can I get alerts for AURA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Aura Biosciences, Inc. (AURA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Aura Biosciences, Inc. is in the Healthcare sector.